NuvationBio

[NuvationBio @nuvationbioinc]

Our Founder and CEO, David Hung, M.D., and CFO, Philippe Sauvage, will highlight the latest developments across our portfolio of innovative oncology programs and connect with the investment community at upcoming conferences.

See more: https://t.co/KdfPEjGNwg

#biotech #cancer #oncology

[NuvationBio @nuvationbioinc]

We’re excited to announce that the FDA has granted Fast Track Designation for our investigational therapy for IDH1-mutant glioma, which we believe reinforces its potential to address significant unmet medical needs for patients with this disease.

Learn more: https://t.co/hLhxyFIFBd

[NuvationBio @nuvationbioinc]

Today we reported second quarter 2026 financial results and provided a business update. Join our conference call and webcast at 8:00 a.m. ET and read more here: https://t.co/ZG20cWLS1u

#biotech #cancer #oncology

[NuvationBio @nuvationbioinc]

We’re excited to share new analyses from our pivotal TRUST-I and TRUST-II studies on the efficacy and safety of our medicine across key patient subgroups living with ROS1+ #NSCLC at two major oncology congresses this fall: #WCLC26 and #ESMO26.

Learn more: https://t.co/beBsDyFyYh

[NuvationBio @nuvationbioinc]

Today we announced updated long-term follow-up data from our Phase 2 (J201) study. We also announced the significant expansion of our IDH1-mutant glioma clinical program with two new studies to explore the broad spectrum of this challenging disease.

Learn more: https://t.co/7M57ngdR1y

[NuvationBio @nuvationbioinc]

@PharmExec Thank you for having our team!

[NuvationBio @nuvationbioinc]

At the Jefferies Global Healthcare Conference, our Founder and CEO, David Hung, M.D., and CFO, Philippe Sauvage, will share updates on Nuvation’s progress and how we are working to make an impact for cancer patients. Read more: https://t.co/8hoHh2LAKT

#biotech #cancer #oncology

[NuvationBio @nuvationbioinc]

We’re excited to present new quality of life data from one of our pivotal studies evaluating our treatment for advanced ROS1+ non-small cell lung cancer (#NSCLC), as well as a trial-in-progress poster for our adjuvant study in early-stage ROS1+ NSCLC, at #ASCO26.

Learn more: https://t.co/AOy2WN8q77

[NuvationBio @nuvationbioinc]

We’re headed to #ASCO26 next week! Visit us at booth #35117 to connect with our team and learn more about our programs for ROS1+ #NSCLC and IDH1-mutant glioma.

[NuvationBio @nuvationbioinc]

Today we announced our collaboration with @thermofisher for U.S.-based manufacturing for our FDA-approved ROS1 inhibitor for ROS1-positive non-small cell lung cancer (#NSCLC).

Learn more: https://t.co/yZdiZbHIMT

[NuvationBio @nuvationbioinc]

Today we announced that the U.S. FDA has accepted a supplemental New Drug Application (sNDA) for our treatment for ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC), with a target action date of January 4, 2027. Learn more: https://t.co/X5EhrK5KAg

[NuvationBio @nuvationbioinc]

Our Founder and CEO, David Hung, M.D., and CFO, Philippe Sauvage, will highlight the latest developments across our portfolio of innovative oncology programs and connect with the investment community at upcoming conferences. See more: https://t.co/QULoj3KXVU

#biotech #cancer #oncology

[NuvationBio @nuvationbioinc]

Today we reported first quarter 2026 financial results and provided a business update. Join our conference call and webcast at 4:30 p.m. ET and read more here: https://t.co/xlryjemMgh

#biotech #cancer #oncology

[NuvationBio @nuvationbioinc]

As we recognize #BrainTumorAwarenessMonth in May, we stand with the patients, families and caregivers who have been impacted by brain cancer, and the amazing advocacy groups supporting this community:
@NBTStweets, @theABTA, and @EndBrainCancer

#GoGrayinMay

[NuvationBio @nuvationbioinc]

#ICYMI, last week we presented long-term clinical data at #AACR26 highlighting the efficacy and safety of our #ROS1 inhibitor in TKI-naive and TKI-pretreated patients with ROS1-positive non-small cell lung cancer (#NSCLC). Learn more: https://t.co/h752kshPJy

[NuvationBio @nuvationbioinc]

Last week we were grateful for the opportunity to present updated data from our TRUST-I & TRUST-II studies at #AACR26, connect with members of the #oncology community from around the world, and dive into the latest research transforming cancer care.

[NuvationBio @nuvationbioinc]

The latest updates to the @NCCN Clinical Practice Guidelines in Oncology for Central Nervous System (CNS) cancers include our next-generation treatment as a systemic option for patients with ROS1+ non-small cell lung cancer with brain metastases.

Learn more: https://t.co/UpFC3vilb7

[NuvationBio @nuvationbioinc]

At #AACR26, we presented new preclinical data on our FDA-approved ROS1 inhibitor that suggested its ability to reduce the invasive capacity of lung cancer cells based on its TRKB inhibition profile.
Learn more about these mechanistic findings: https://t.co/OWMTnr4v4F

[NuvationBio @nuvationbioinc]

Live from #AACR26: We’re presenting new data highlighting the efficacy and safety of our ROS1 inhibitor in TKI-naive and TKI-pretreated patients with ROS1+ #NSCLC. Learn more: https://t.co/OWMTnr4v4F.

[NuvationBio @nuvationbioinc]

Tune into our first quarter 2026 earnings and business update conference call on Monday, May 4, 2026, at 4:30 p.m. ET.

Get the details: https://t.co/UiRkT6YS1j

#biotech #cancer #oncology